PDCD1 and COVID-19: Ex vivo studies using T cells from COVID-19 patients have demonstrated that PD-1 blockade reverses the increase in expression of the positive costimulatory marker OX40 in the CD8+ T cell fraction observed in patients who have recovered from COVID-19.